First-Ever Oral Pill Approved for Postpartum Depression Treatment

The Food and Drug Administration has approved a new drug, Zurzuvae, for the treatment of severe postpartum depression (PPD), which is expected to launch in the fourth quarter of 2023. PPD can interfere with new mothers’ ability to care for themselves and their babies, according to Suzy Lipinski, M.D., a board-certified OBGYN at Obstetrix of Colorado, part of Pediatrix® Medical Group. “This is a severe, potentially life-threatening pregnancy complication that has a lot of stigma, which limits women seeking treatment,” said Dr. Lipinski. “It is my genuine hope that as this drug reaches the market, it will open the doors for more conversations, treatment, and acceptance of this illness.”

View the full story on Verywell Health